MedTrace Logo

Safety Validation of EndoSWIR Device

NCT04274309 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2020-07-23

No results posted yet for this study

Summary

Head and neck cancer has an incidence of 600,000 cases per year worldwide (6th among cancers) and cause 380,000 death per year. Surgical resection is guided by the surgeon's inspection and palpation of the tumor. The prognosis of patients depends on the quality of the lesion's resection. The ENDOSWIR dispositive developed by engineers of Atomic Energy Comity of Grenoble allows for reliable and accurate analysis of tumor margins.

The camera provides a spectral analysis of the tissues according to their composition. We want to show that the prognosis of patients is improved by the use of this device. For that we need to prove first that it is not toxic for tissue analysis.

Conditions

  • Optical Guided Surgery

Interventions

DEVICE

EndoSWIR

Exposition of the respected tissues to the camera

Sponsors & Collaborators

  • Institut National de la Santé et de la Recherche Médicale, Institute for Advanced Biosciences

    collaborator UNKNOWN

  • Commissariat A L'energie Atomique

    collaborator OTHER_GOV

  • Lynred

    collaborator UNKNOWN

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • Christian RIGHINI · University Hospital, Grenoble

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-07-21
Primary Completion
2021-05-01
Completion
2021-05-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04274309 on ClinicalTrials.gov